Skip to main content

Teleflex Value Stock - Dividend - Research Selection

Teleflex

ISIN: US8793691069 , WKN: 855853

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Are Teleflex Incorporated's (NYSE:TFX) Mixed Financials Driving The Negative Sentiment?

2025-05-02
Teleflex (NYSE:TFX) has had a rough three months with its share price down 30%. It seems that the market might have...

Teleflex Inc (TFX) Q1 2025 Earnings Call Highlights: Navigating Challenges and Strategic Growth ...

2025-05-02
Despite a revenue decline, Teleflex Inc (TFX) focuses on strategic initiatives and market expansion to drive future growth.

Q1 2025 Teleflex Inc Earnings Call

2025-05-02
Q1 2025 Teleflex Inc Earnings Call

Teleflex Investor News: Rosen Law Firm Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation - TFX

2025-05-01
NEW YORK, May 1, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor...

TFX Investors Have Opportunity to Join Teleflex Incorporated Fraud Investigation with the Schall Law Firm

2025-05-01
LOS ANGELES, May 1, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teleflex Incorporated...

Teleflex Incorporated (TFX) Q1 2025 Earnings Call Transcript

2025-05-01
Teleflex Incorporated (NYSE:TFX) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsLawrence Keusch - VP-IR & Strategy...

Teleflex (NYSE:TFX) Reports Q1 In Line With Expectations

2025-05-01
Medical technology company Teleflex (NYSE:TFX) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 5% year on year to $700.7 million. Its non-GAAP profit of $2.91 per share was 0.9% above analysts’ consensus estimates.

Here's What Key Metrics Tell Us About Teleflex (TFX) Q1 Earnings

2025-05-01
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teleflex (TFX) Tops Q1 Earnings and Revenue Estimates

2025-05-01
Teleflex (TFX) delivered earnings and revenue surprises of 1.04% and 0.22%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Teleflex: Q1 Earnings Snapshot

2025-05-01
On a per-share basis, the Wayne, Pennsylvania-based company said it had profit of $2.07. Earnings, adjusted for one-time gains and costs, came to $2.91 per share. The results surpassed Wall Street expectations.